SIGA’S SMALLPOX WIN IS NO MONKEY BUSINESS!

$SIGA

Siga Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company scored an FDA approval for its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). Given the rise of Monkeypox cases around the globe, can the Company leverage its expertise to make the most of the emerging opportunity?

Read on to find out more!

https://www.aviseanalytics.com/sigas-smallpox...-business/